Abstract
Our understanding of the heterogeneity and genetic characteristics of CRPC demonstrates underlying their complexity, which has been thought to be associated with their intractability. Recent advance of integrative next generation sequencing unveiled the extensive mutational landscape of metastatic CRPC, many of which can be a targetable mutation and been linked to ongoing clinical trials. Molecular stratification of patient groups will clearly be critical to successful drug development and clinical trials from the view point of precision medicine. In this review, we discuss the potential of new targeted approach to impact the clinical management of CRPC.
| Original language | English |
|---|---|
| Title of host publication | Hormone Therapy and Castration Resistance of Prostate Cancer |
| Publisher | Springer Singapore |
| Pages | 375-385 |
| Number of pages | 11 |
| ISBN (Electronic) | 9789811070136 |
| ISBN (Print) | 9789811070129 |
| DOIs | |
| Publication status | Published - 2018 May 11 |
Keywords
- AR signaling pathway
- Cell-free DNA
- Circulating tumor cells
- CRPC
- DNA repair pathway
- Liquid biopsy
- PI3K-PTEN-AKT-mTOR pathway
- Precision medicine
- WNT pathway
ASJC Scopus subject areas
- Medicine(all)
Fingerprint Dive into the research topics of 'New targeted approach to CRPC'. Together they form a unique fingerprint.
Cite this
Kosaka, T., & Oya, M. (2018). New targeted approach to CRPC. In Hormone Therapy and Castration Resistance of Prostate Cancer (pp. 375-385). Springer Singapore. https://doi.org/10.1007/978-981-10-7013-6_38